REG - Destiny Pharma PLC - Notice of Results and Investor Presentation

Destiny PharmaAnnouncement

03/04/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230403:nRSC9334Ua&default-theme=true

RNS Number : 9334U  Destiny Pharma PLC  03 April 2023

Destiny Pharma plc

("Destiny Pharma" or "the Company")

 

Notice of Full Year Results and Investor Presentation

 

Brighton, United Kingdom - 30 March 2023 - Destiny Pharma plc (AIM: DEST),
a clinical stage innovative biotechnology company focused on the development
of novel medicines that can prevent life threatening infections, will
announce its financial results for the year ended 31 December 2022, on
Thursday 13 April 2023.

 

Neil Clark, Chief Executive Officer and Shaun Claydon, Chief Financial
Officer, will provide a live presentation on the same day, at 10:30 am BST,
followed by a Q&A session accessible via the Investor Meet Company
platform.

 

The presentation is open to analysts and all existing and potential new
shareholders. Questions can be submitted pre-event via the Investor Meet
Company dashboard up until 09:00 am BST the day before the meeting, or at any
time during the live presentation.

 

Investors can sign up to Investor Meet Company for free, and add to
meet Destiny Pharma
plc via: https://www.investormeetcompany.com/destiny-pharma-plc/register-investor
(https://www.investormeetcompany.com/destiny-pharma-plc/register-investor)

 

Investors who already follow Destiny Pharma plc on the Investor Meet Company
platform will automatically be invited.

 

For further information, please contact:

 

Destiny Pharma plc
Neil Clark, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440
pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

 

Optimum Strategic Communications
Mary Clark / Nick Bastin / Jonathan Edwards / Eleanor Cooper

+44 (0) 7931 5000 66
DestinyPharma@optimumcomms.com (mailto:destinypharma@optimumcomms.com)

 

finnCap Ltd (Nominated Advisor and Joint Broker)
Geoff Nash / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0) 207 220 0500

 

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

MC Services AG
Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

 

Stern IR - US

Janhavi Mohite

+1-212-362-1200

janhavi.mohite@sternir.com

 

 

 

 

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused
on the development of novel medicines that can prevent life-threatening
infections. Its pipeline has novel microbiome-based biotherapeutics and XF
drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US and also XF-73 nasal gel, which
has recently completed a positive Phase 2 clinical trial targeting the
prevention of post-surgical staphylococcal hospital infections including MRSA.
It is also co-developing SPOR-COV(TM), a novel, biotherapeutic product for the
prevention of COVID-19 and other viral respiratory infections and has earlier
grant funded XF drug research projects.

For further information on the company, please visit www.destinypharma.com
(http://www.destinypharma.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORUAUWROSUOORR